Forschung am Chirurgischen Zentrum

Combined regression score predicts outcome after neoadjuvant treatment of oesophageal cancer.

Damanakis AI, Gebauer F, Stapper A, Schlößer HA, Ghadimi M, Schmidt T, Schiffmann LM, Fuchs H, Zander T, Quaas A, Bruns CJ, Schroeder W.

Br J Cancer. 2023 Mar 25. doi: 10.1038/s41416-023-02232-y. Online ahead of print.

PMID: 36966235

Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma.

Damanakis AI, Wahler I, Fuchs H, Löser H, Schröder W, Zander T, Chon SH, Bruns C, Quaas A, Gebauer F.

Sci Rep. 2022 Dec 1;12(1):20745. doi: 10.1038/s41598-022-25071-y.

PMID: 36456612 Free PMC article.

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC).

Gebauer F, Damanakis AI, Popp F, Quaas A, Kütting F, Lutz K, Held S, Deuß B, Göser T, Waldschmidt D, Bruns C.

BMC Cancer. 2021 Nov 18;21(1):1239. doi: 10.1186/s12885-021-08966-3.

PMID: 34794396 Free PMC article. Clinical Trial.

Proposal for a definition of "Oligometastatic disease in pancreatic cancer".

Damanakis AI, Ostertag L, Waldschmidt D, Kütting F, Quaas A, Plum P, Bruns CJ, Gebauer F, Popp F.

BMC Cancer. 2019 Dec 30;19(1):1261. doi: 10.1186/s12885-019-6448-9.

PMID: 31888547 Free PMC article.